AGER and Insulin resistance: Combination therapy with nateglinide, a rapid-onset/short-duration insulinotropic agent and telmisartan, an angiotensin II type 1 receptor blocker with partial agonistic activity of peroxisome proliferator-activated receptor-γ (PPARγ), improves hepatic insulin resistance in Zucker fatty rats by suppressing the AGE-RAGE axis as well [28].